Clinical trial
Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI…
NCT00299520 · Arpida AG, Industry · Completed
Key facts
| NCT number | NCT00299520 |
|---|---|
| Title | Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1) |
| Official title | Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections.(ASSIST-1) |
| Lead sponsor | Arpida AG, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Complicated Skin and Skin Structure Infection |
| Intervention type | Drug |
| Interventions | intravenous iclaprim or intravenous linezolid |
| Start date | Jun 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Mar 7, 2006 |
| Last update posted | Apr 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: